Biosimilar sales are expected to nearly triple in the coming years, from about $2.5 billion last year to more than $6.5 billion in 2024, according to an S&P Global Ratings analysis cited by STAT.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,